AMGN vs CLDI: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

AMGN is the larger of the two ($250.67B market cap): the incumbent the market prices for continued execution (18.54x forward earnings, beta 0.42). CLDI is the smaller challenger ($2.53M), priced similarly on forward earnings (-0.77x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

AMGN vs CLDI: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAMGNCLDIWhat it tells you
Market cap$250.67B$2.53MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E18.54-0.77Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.421.37Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range88% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book17.470.46How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how AMGN and CLDI affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMGN and CLDI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMGN and CLDI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Amgen (AMGN) do?

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

Full AMGN guide

What does Calidi Biotherapeutics (CLDI) do?

Calidi Biotherapeutics, Inc. is an immuno-oncology company based in San Diego, California, developing therapies that use oncolytic viruses, and in some programs cell-based delivery, to target hard-to-treat cancers. Its founding approach was to shield therapeutic viruses inside stem cells so they can survive the immune system long enough to reach and destroy tumors, and its newer RedTail platform pursues the same goal with an engineered enveloped virus designed for intravenous delivery to metastatic sites. In its August 2026 update the company described RedTail as its lead platform: CLD-401, which carries an IL-15 superagonist payload, is in IND-enabling studies for metastatic non-small cell lung cancer, head and neck cancer and other solid tumors, and after positive pre-IND feedback from the FDA it is targeting first patient dosing in the first quarter of 2027. A second RedTail compound, CLD-501, adds an in situ TROP-2 T-cell engager and was shown preclinically at ASCO 2026. The earlier pipeline includes CLD-101 (NeuroNova), studied in Phase 1 for high-grade glioma, and CLD-201 (SuperNova), an allogeneic stem-cell-loaded viral therapy for solid tumors such as soft tissue sarcoma; the 2026 updates focus on RedTail and say little about those programs. The company generates no product revenue and is years away from any potential approval.

Full CLDI guide

AMGN vs CLDI: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
  • CLDI drivers: Stem-Cell-Shielded Virotherapy Platform; CLD-201 SuperNova and FDA Designations.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. For CLDI, calidi is a pre-revenue, preclinical-to-early-clinical nano-cap whose value depends almost entirely on early-stage outcomes, so a single failure, safety signal, or program delay could sharply reduce the stock.

AMGN or CLDI: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMGN if you believe its drivers more; CLDI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMGN and CLDI guides.

AMGN vs CLDI: the full fundamentals

AMGN. As of October 16, 2026, Amgen trades at about 27x trailing GAAP earnings and about 18x forward earnings, with EV/EBITDA near 16x, a rerating from early 2026 after the shares gained about a third. The dividend yield has fallen to about 2.3% as the price rose. Consensus for the Q3 2026 report on November 3 is adjusted EPS of ~$5.76 on ~$10.06 billion of revenue; the 29 analysts covering the stock have an average target of about $395, below the current price.

CLDI. A pre-revenue biotech like Calidi cannot be valued on earnings, because there are none; P/E is not meaningful. Investors who study these companies typically weigh the cash runway against the quarterly burn rate, the timing and probability of clinical catalysts (here, a planned CLD-401 first-in-human study in early 2027), and the dilution required to fund it. With a market value near $3 million and cash of a similar size, the market is assigning little value to the pipeline, and the listing-compliance deadline, going-concern doubt and repeated reverse splits mean financing risk dominates any assessment.

Headline figures (approximate, October 2026): AMGN shows revenue (ttm) ~$38.1 billion, revenue growth (q2 2026, yoy) ~9.5%, operating margin ~36%, net income (ttm) ~$8.7 billion; CLDI shows revenue None (no approved products; pre-revenue), net loss (q2 2026) ~$4.2 million ($2.94 per share), vs ~$5.7 million a year earlier, net loss (ttm) ~$23.5 million, cash & equivalents ~$4.1 million at June 30, 2026 (plus ~$0.2 million restricted); ~$1.2 million raised in September 2026.

The bottom line: AMGN vs CLDI

AMGN and CLDI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMGN and CLDI exposure against your real portfolio. It is not an investment adviser.

Wondering how AMGN or CLDI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Amgen

Ask Walnut's AI anything about AMGN and see how it fits what you own.

FAQ

What is the difference between AMGN and CLDI?

+

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Calidi Biotherapeutics, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AMGN or CLDI the better stock?

+

Neither is universally better. AMGN is the larger incumbent; CLDI is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AMGN or CLDI?

+

On forward P/E (as of November 2026), AMGN trades at 18.54x and CLDI at -0.77x, so CLDI is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AMGN and CLDI?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AMGN vs CLDI?

+

AMGN: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition left Amgen with about ~$57 billion of total debt against ~$14 billion of cash as of mid-2026. After a 33% year-to-date gain, the share price of $436 sits above the ~$395 average analyst target, and consensus expects only about 5% EPS growth in 2026 and 6% in 2027, so the valuation now assumes more than the near-term numbers show. Litigation, manufacturing, and safety risks are inherent to the industry. CLDI: Calidi is a pre-revenue, preclinical-to-early-clinical nano-cap whose value depends almost entirely on early-stage outcomes, so a single failure, safety signal, or program delay could sharply reduce the stock. The company has reported substantial doubt about its ability to continue as a going concern, held only about $4.1 million in cash at June 30, 2026 against quarterly net losses near $4 million, and funds itself through repeated dilutive equity raises that erode existing shareholders; it also carries a large warrant overhang. It completed a 1-for-12 reverse split in August 2025 and a 1-for-16 reverse split in July 2026, yet the shares still fell to about $0.86 by October 16, 2026, down roughly 95% for the year. In September 2026 NYSE American notified it that stockholders' equity of $3.1 million is below the $4.0 million standard; if its compliance plan (due October 21, 2026) is not accepted, delisting proceedings would begin. There is no product revenue, no profit, and no certainty that any program will ever be approved or commercialized. This is among the most speculative categories of stock, and a total or near-total loss is a realistic outcome.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMGN or CLDI; figures are approximate and dated (as of November 2026). Verify current data before investing.